Haruko Shirato, Yuichi Someya, Masaki Ochiai, Yoshinobu Horiuchi, Motohide Takahashi, Naokazu Takeda, Kengo Wakabayashi, Yasumitsu Ouchi, Yoshihiro Ota, Yoshio Tano, Shinobu Abe, Shudo Yamazaki, Takaji Wakita
As one aspect of its campaign to eradicate poliomyelitis, the World Health Organization (WHO) has encouraged development of the inactivated polio vaccine (IPV) derived from the Sabin strains (sIPV) as an option for an affordable polio vaccine, especially in low-income countries. The Japan Poliomyelitis Research Institute (JPRI) inactivated three serotypes of the Sabin strains and made sIPV preparations, including serotypes 1, 2 and 3 D-antigens in the ratio of 3:100:100. The National Institute of Infectious Diseases, Japan, assessed the immunogenic stability of these sIPV preparations in a rat potency test, according to an evaluation method recommended by the WHO...
September 8, 2014: Vaccine